Historical Valuation
Climb Bio Inc (CLYM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.41. The fair price of Climb Bio Inc (CLYM) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：5.04
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Climb Bio Inc (CLYM) has a current Price-to-Book (P/B) ratio of 1.44. Compared to its 3-year average P/B ratio of 0.92 , the current P/B ratio is approximately 56.51% higher. Relative to its 5-year average P/B ratio of 0.91, the current P/B ratio is about 58.89% higher. Climb Bio Inc (CLYM) has a Forward Free Cash Flow (FCF) yield of approximately -24.81%. Compared to its 3-year average FCF yield of -26.53%, the current FCF yield is approximately -6.47% lower. Relative to its 5-year average FCF yield of -27.44% , the current FCF yield is about -9.58% lower.
P/B
Median3y
0.92
Median5y
0.91
FCF Yield
Median3y
-26.53
Median5y
-27.44
Competitors Valuation Multiple
AI Analysis for CLYM
The average P/S ratio for CLYM competitors is 7.51, providing a benchmark for relative valuation. Climb Bio Inc Corp (CLYM.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CLYM
1Y
3Y
5Y
Market capitalization of CLYM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CLYM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CLYM currently overvalued or undervalued?
Climb Bio Inc (CLYM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.41. The fair price of Climb Bio Inc (CLYM) is between to according to relative valuation methord.
What is Climb Bio Inc (CLYM) fair value?
CLYM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Climb Bio Inc (CLYM) is between to according to relative valuation methord.
How does CLYM's valuation metrics compare to the industry average?
The average P/S ratio for CLYM's competitors is 7.51, providing a benchmark for relative valuation. Climb Bio Inc Corp (CLYM) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Climb Bio Inc (CLYM) as of Jan 10 2026?
As of Jan 10 2026, Climb Bio Inc (CLYM) has a P/B ratio of 1.44. This indicates that the market values CLYM at 1.44 times its book value.
What is the current FCF Yield for Climb Bio Inc (CLYM) as of Jan 10 2026?
As of Jan 10 2026, Climb Bio Inc (CLYM) has a FCF Yield of -24.81%. This means that for every dollar of Climb Bio Inc’s market capitalization, the company generates -24.81 cents in free cash flow.
What is the current Forward P/E ratio for Climb Bio Inc (CLYM) as of Jan 10 2026?
As of Jan 10 2026, Climb Bio Inc (CLYM) has a Forward P/E ratio of -4.62. This means the market is willing to pay $-4.62 for every dollar of Climb Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Climb Bio Inc (CLYM) as of Jan 10 2026?
As of Jan 10 2026, Climb Bio Inc (CLYM) has a Forward P/S ratio of 0.00. This means the market is valuing CLYM at $0.00 for every dollar of expected revenue over the next 12 months.